Filing Flows

Filing Flows › Maravai Lifesciences Holdings (MRVI) › Next earnings date

Maravai Lifesciences Holdings (MRVI) earnings: beat the estimate

Maravai Lifesciences Holdings (MRVI) reported on Nov 4, 2026 and beat the EPS estimate: −$0.03 against −$0.06 (+46.3%). Revenue was $45.9M for Q3 2026, +10% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+46.3% vs estimate
Beat rate100%

The last report

Maravai Lifesciences Holdings reported revenue of $45.9M for the third quarter 2026 (+10% Y/Y), net loss $24.0M: TriLink $28.4M, Cygnus $17.5M. How it makes money → · Every quarter →

Maravai Lifesciences Holdings: EPS against the estimate, last 5 reportsMaravai Lifesciences Holdings: EPS against the estimate, last 5 reportsEstimateReported−$0.08−$0.08Nov 25−$0.07−$0.04Feb 26−$0.05$0.01May 26−$0.04−$0.02Aug 26−$0.06−$0.03Nov 26
Latest (Nov 26): Estimate −$0.06, Reported −$0.03.

Maravai Lifesciences Holdings' latest quarter

Maravai Lifesciences Holdings, Q3 2026: revenue $45.9M (+10% year over year), operating margin -45.0%, net loss $24.0M, operating cash flow $5.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Maravai Lifesciences Holdings beat earnings?

Maravai Lifesciences Holdings (MRVI) reported on Nov 4, 2026 and beat the EPS estimate: −$0.03 against −$0.06 (+46.3%).

When does MRVI report earnings?

The next date is not set yet.

Does Maravai Lifesciences Holdings usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.